Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the association of serum organochlorine pesticides (OCPs) and organophosphorus pesticides (OPs) levels and GSTM1/GSTT1 gene polymorphism with bladder cancer (BC).
|
31009110 |
2019 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the impact of GSTM1 null genotype on bladder cancer patients' outcome.
|
31646988 |
2019 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis suggested that GSTM1-null genotype is associated with an increased bladder cancer risk in the Chinese individuals.
|
30539835 |
2018 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
With regard to BC, an overall odds ratio (OR) of 2.07 [95% confidence interval (CI): 1.38-3.09] for those with GSTM1 and an OR of 2.07 (95% CI: 1.38-3.09) for those with GSTT1 null genotype were reported when exposed to polycyclic aromatic hydrocarbons (PAHs).
|
28403014 |
2018 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The common deletion of the glutathione S-transferase Mu 1 (GSTM1) gene in humans has been shown to be involved in xenobiotic metabolism and associated with bladder cancer.
|
29695243 |
2018 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the GSTM1-null, GSTT1-null and dual-null GSTM1-GSTT1 genotypes might be associated with the onset of bladder cancer, but additional genetic-epidemiological studies should be conducted to explore this association further.
|
30419877 |
2018 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most relevant polymorphisms for occupational bladder cancer risk were GSTM1 and UGT1A, especially when co-occurring (GSTM1 negative and rs11892031[A/A]: 48% cases vs. 38% controls, OR 1.47, 95% CI 0.99-2.20).
|
28696839 |
2017 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Stratified analyses of population-based associations indicated increased bladder cancer risk associated with GSTM1-null and GSTM1/GSTT1 double-null genotypes in hospital-based and population-based studies.
|
27911277 |
2017 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The phase II enzymes N-acetyltransferase 2 (NAT2), glutathione S-transferases M1 (GSTM1), and T1 (GSTT1) and the single nucleotide polymorphism (SNP) rs11892031[A/C] reported to be associated with bladder cancer in genome-wide association studies were genotyped.
|
28696895 |
2017 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Data indicate that GSTM1 is a susceptibility factor for environmentally triggered bladder cancer rather than for smoking-mediated bladder cancer.
|
28696897 |
2017 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, common polymorphisms in GSTA1, GSTM1 and GSTT1 are associated with susceptibility to BC in individuals from BEN areas of Serbia.
|
27568660 |
2016 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow genotype, together with GSTM1 null genotype facilitated the development of bladder cancer in almost all ethnic groups.
|
26854433 |
2016 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Besides, meaningful association between individuals who carried the GSTM1 null genotype and increased BCa risk was detected (OR = 1.39, 95%CI 1.28-1.51).
|
27631264 |
2016 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P interaction ≤ .001), rs11892031 (UGT1A, P interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P interaction = .03).
|
26374428 |
2015 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no association between bladder cancer and GSTM1 polymorphism (ORs = 0.64, 95% CI = 0.32-1.29), but the probability of bladder cancer in patients with GSTT1 null genotype (67.9%), was significantly higher from the probability of bladder cancer with GSTT1 normal genotype (43.0%) statistically (ORs = 2.8, 95% CI = 1.16-6.75).
|
25284638 |
2015 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The glutathione S-transferase M1-null genotype also enhanced the risk of bladder cancer among subjects exposed to solvents (OR = 6,5, 95% CI = 2.1-19.7, p = 0.001).
|
24914957 |
2014 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that seven bladder cancer risk-associated variants (rs9642880, rs2294008, rs798766, rs1495741, GSTM1 null, rs17674580 and rs10936599) may be used, collectively, to effectively measure inherited risk for bladder cancer.
|
24740636 |
2014 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The cumulative meta-analyses showed a trend of more obvious association between the GSTM1 null variant and risk of bladder cancer in the Chinese Han population as data accumulated by year.
|
24022663 |
2014 |
Bladder Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GSTM1-null and GSTA1-low activity genotypes are associated with enhanced oxidative damage in bladder cancer.
|
23394311 |
2013 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, in association with smoking, both low activity GSTA1 and GSTM1-null genotype increase individual susceptibility to bladder cancer.
|
24075358 |
2013 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The GSTP1 Val/Val genotype was significantly associated with bladder cancer (OR = 4.32, 95% CI: 2.64-6.34), whereas the association observed for GSTM1 null (OR = 1.32, 95% CI: 0.82-2.62; P = 0.67) and GSTT1 null genotype (OR = 1.18, 95% CI: 0.79-1.67; P = 0.74) did not reach statistical significance.
|
22154357 |
2013 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that inherited absence of GSTT1 gene may be associated with bladder cancer susceptibility, and specific combinations of GSTM1, GSTT1 and CYP1B1 gene polymorphisms may modify bladder cancer risk in the Turkish population, without any association being observed for CYP1A1 gene polymorphism and bladder cancer risk.
|
23886208 |
2013 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Combination of the high-risk genotypes (GSTM1 null + GSTT1 null + GSTP1 313 A/G or G/G) demonstrated further increase in the BC risk (OR = 6.64, 95 %CI = 3.63-12.16).
|
23054023 |
2013 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
When combined with the GSTM1 null genotype, a remarkably increased risk was found for BC.
|
22339266 |
2012 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study was aimed at examining the local distribution of GSTM1, GSTT1, MDR1, and VEGF gene polymorphisms as possible risk factors contributing to the development of bladder cancer among the population from Canary Islands, Spain.
|
21292509 |
2012 |